Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
Most Recent Events
- 29 Nov 2023 Status changed from recruiting to completed.
- 03 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Jun 2022.
- 03 Dec 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2021.